<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Imaging</journal-id><journal-title-group><journal-title>Cancer Imaging</journal-title></journal-title-group><issn pub-type="ppub">1740-5025</issn><issn pub-type="epub">1470-7330</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39985091</article-id><article-id pub-id-type="pmc">PMC11844016</article-id>
<article-id pub-id-type="publisher-id">836</article-id><article-id pub-id-type="doi">10.1186/s40644-025-00836-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Total lesion glycolysis of primary tumor and lymphnodes is a strong predictor for development of distant metastases in oropharyngeal carcinoma patients with independent validation in automatically delineated lesions</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3109-0662</contrib-id><name><surname>Zschaeck</surname><given-names>Sebastian</given-names></name><address><email>Sebastian.Zschaeck@charite.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hajiyianni</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hausmann</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nikulin</surname><given-names>Pavel</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kukuk</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Furth</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Cegla</surname><given-names>Paulina</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Lombardo</surname><given-names>Elia</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Kazmierska</surname><given-names>Joanna</given-names></name><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Holzgreve</surname><given-names>Adrien</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Strouthos</surname><given-names>Iosif</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Stromberger</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Belka</surname><given-names>Claus</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff14">14</xref><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Baumann</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Krause</surname><given-names>Mechthild</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff17">17</xref><xref ref-type="aff" rid="Aff18">18</xref><xref ref-type="aff" rid="Aff19">19</xref><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name><surname>Landry</surname><given-names>Guillaume</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Cholewinski</surname><given-names>Witold</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Kotzerke</surname><given-names>Jorg</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>Zips</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff22">22</xref><xref ref-type="aff" rid="Aff23">23</xref><xref ref-type="aff" rid="Aff24">24</xref><xref ref-type="aff" rid="Aff25">25</xref><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name><surname>van den Hoff</surname><given-names>J&#x000f6;rg</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Hofheinz</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001w7jn25</institution-id><institution-id institution-id-type="GRID">grid.6363.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2218 4662</institution-id><institution>Department of Radiation Oncology, </institution><institution>Charit&#x000e9;&#x02013; Universit&#x000e4;tsmedizin Berlin, corporate member of Freie Universit&#x000e4;t Berlin, Humboldt-Universit&#x000e4;t zu Berlin, Berlin Institute of Health, </institution></institution-wrap>Augustenburger Platz 1, 13353 Berlin, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001w7jn25</institution-id><institution-id institution-id-type="GRID">grid.6363.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2218 4662</institution-id><institution>Berlin Institute of Health at Charit&#x000e9;, </institution><institution>Universit&#x000e4;tsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charit&#x000e9; (Junior) Clinician Scientist Program, </institution></institution-wrap>Berlin, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042aqky30</institution-id><institution-id institution-id-type="GRID">grid.4488.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2111 7257</institution-id><institution>Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, </institution><institution>Technische Universit&#x000e4;t Dresden, </institution></institution-wrap>Dresden, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02pqn3g31</institution-id><institution-id institution-id-type="ISNI">0000 0004 7865 6683</institution-id><institution>German Cancer Consortium (DKTK), partner site Dresden, Germany, and German Cancer Research Center (DKFZ) Heidelberg, </institution></institution-wrap>Heidelberg, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042aqky30</institution-id><institution-id institution-id-type="GRID">grid.4488.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2111 7257</institution-id><institution>OncoRay&#x02013; National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, </institution><institution>Technische Universit&#x000e4;t Dresden, Helmholtz-Zentrum Dresden&#x02013; Rossendorf, </institution></institution-wrap>Dresden, Germany </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01zy2cs03</institution-id><institution-id institution-id-type="GRID">grid.40602.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 2158 0612</institution-id><institution>Institute of Radiopharmaceutical Cancer Research, </institution><institution>Helmholtz-Zentrum Dresden-Rossendorf, </institution></institution-wrap>Dresden, Germany </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0493xsw21</institution-id><institution-id institution-id-type="GRID">grid.484013.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 6879 971X</institution-id><institution>Department of Nuclear Medicine, </institution><institution>Charit&#x000e9; Universit&#x000e4;tsmedizin Berlin, Freie Universit&#x000e4;t Berlin and Humboldt Universit&#x000e4;t zu Berlin, Berlin Institute of Health, </institution></institution-wrap>Berlin, Germany </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0243nmr44</institution-id><institution-id institution-id-type="GRID">grid.418300.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 1088 774X</institution-id><institution>Department of Nuclear Medicine, </institution><institution>Greater Poland Cancer Centre, </institution></institution-wrap>Poznan, Poland </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05591te55</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution>Department of Radiation Oncology, </institution><institution>LMU University Hospital, LMU Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02zbb2597</institution-id><institution-id institution-id-type="GRID">grid.22254.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2205 0971</institution-id><institution>Electroradiology Department, </institution><institution>University of Medical Sciences, </institution></institution-wrap>Poznan, Poland </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0243nmr44</institution-id><institution-id institution-id-type="GRID">grid.418300.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 1088 774X</institution-id><institution>Radiotherapy Department II, </institution><institution>Greater Poland Cancer Centre, </institution></institution-wrap>Poznan, Poland </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05591te55</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution>Department of Nuclear Medicine, </institution><institution>LMU University Hospital, LMU Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04xp48827</institution-id><institution-id institution-id-type="GRID">grid.440838.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0642 7601</institution-id><institution>Department of Radiation Oncology, German Oncology Center, </institution><institution>European University Cyprus, </institution></institution-wrap>Limassol, Cyprus </aff><aff id="Aff14"><label>14</label>Bavarian Cancer Research Center (BZKF), Munich, Germany </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02pqn3g31</institution-id><institution-id institution-id-type="ISNI">0000 0004 7865 6683</institution-id><institution>German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and LMU University Hospital Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04cdgtt98</institution-id><institution-id institution-id-type="GRID">grid.7497.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0492 0584</institution-id><institution>Division of Radiooncology/Radiobiology, </institution><institution>German Cancer Research Center (DKFZ), </institution></institution-wrap>Heidelberg, Germany </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02pqn3g31</institution-id><institution-id institution-id-type="ISNI">0000 0004 7865 6683</institution-id><institution>German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and LMU University Hospital Munich, </institution></institution-wrap>Heidelberg, Germany </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042aqky30</institution-id><institution-id institution-id-type="GRID">grid.4488.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2111 7257</institution-id><institution>Faculty of Medicine and University Hospital Carl Gustav Carus, </institution><institution>Technische Universit&#x000e4;t Dresden, </institution></institution-wrap>Dresden, Germany </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01zy2cs03</institution-id><institution-id institution-id-type="GRID">grid.40602.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 2158 0612</institution-id><institution>Helmholtz Association/Helmholtz-Zentrum Dresden - Rossendorf (HZDR), </institution></institution-wrap>Dresden, Germany </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01zy2cs03</institution-id><institution-id institution-id-type="GRID">grid.40602.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 2158 0612</institution-id><institution>Institute of Radiooncology, </institution><institution>Helmholtz-Zentrum Dresden-Rossendorf, </institution></institution-wrap>Dresden, Germany </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042aqky30</institution-id><institution-id institution-id-type="GRID">grid.4488.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2111 7257</institution-id><institution>Department of Nuclear Medicine, </institution><institution>University Hospital Carl Gustav Carus, Technische Universit&#x000e4;t Dresden, </institution></institution-wrap>Dresden, Germany </aff><aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04cdgtt98</institution-id><institution-id institution-id-type="GRID">grid.7497.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0492 0584</institution-id><institution>German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charit&#x000e9;&#x02013; Universit&#x000e4;tsmedizin Berlin, </institution></institution-wrap>Berlin, Germany </aff><aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04cdgtt98</institution-id><institution-id institution-id-type="GRID">grid.7497.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0492 0584</institution-id><institution>National Tumor Center Berlin (NCT), Partner Site Berlin, Germany: German Cancer Research Center (DKFZ), </institution></institution-wrap>Heidelberg, Germany </aff><aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001w7jn25</institution-id><institution-id institution-id-type="GRID">grid.6363.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2218 4662</institution-id><institution>Charit&#x000e9; Comprehensive Cancer, Charit&#x000e9; Universit&#x000e4;tsmedizin Berlin, </institution></institution-wrap>Berlin, Germany </aff><aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001w7jn25</institution-id><institution-id institution-id-type="GRID">grid.6363.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2218 4662</institution-id><institution>Berlin Institute of Health, </institution><institution>Charit&#x000e9; Universit&#x000e4;tsmedizin Berlin, </institution></institution-wrap>Berlin, Germany </aff><aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04p5ggc03</institution-id><institution-id institution-id-type="GRID">grid.419491.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 1014 0849</institution-id><institution>Max-Delbr&#x000fc;ck-Centrum f&#x000fc;r Molekulare Medizin, Helmholtz Association, </institution></institution-wrap>Berlin, Germany </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><elocation-id>18</elocation-id><history><date date-type="received"><day>29</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>6</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025, corrected publication 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Oropharyngeal carcinomas are characterized by an increasing incidence and a relatively good prognosis. Nonetheless, a considerable number of patients develops metachronous distant metastases; identification of these patients is an urgent medical need.</p></sec><sec><title>Methods</title><p id="Par2">This is a retrospective multicenter evaluation of 431 patients. All patients underwent [<sup>18</sup>F]-FDG positron emission tomography (PET). The cohort was split into an explorative group (<italic>n</italic>&#x02009;=&#x02009;366) and a validation group (<italic>n</italic>&#x02009;=&#x02009;65). Lesions were manually delineated in the explorative group and automatically delineated by a convolutional neuronal network (CNN) in the validation group. Quantitative PET parameters standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were calculated for primary tumors (<sub>prim</sub>) and tumor plus lymphnodes (<sub>all</sub>). Association of parameters with freedom from distant metastases (FFDM) and overall survival (OS) was tested by cox regression analyses.</p></sec><sec><title>Results</title><p id="Par3">In the explorative group, univariate analyses revealed an association of metric MTV<sub>prim</sub> (<italic>p</italic>&#x02009;=&#x02009;0.022), MTV<sub>all</sub> (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and TLG<sub>all</sub> (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) with FFDM, binarized parameters were also associated with FFDM (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 and <italic>p</italic>&#x02009;=&#x02009;0.002). Bootstrap analyses revealed a significantly better association of TLG<sub>all</sub> compared to TLG<sub>prim</sub> with FFDM (<italic>p</italic>&#x02009;=&#x02009;0.02). MTV<sub>all</sub> and TLG<sub>all</sub> remained significantly associated with FFDM upon multivariate testing (<italic>p</italic>&#x02009;=&#x02009;0.002, <italic>p</italic>&#x02009;=&#x02009;0.031, respectively). In the validation group, the cutoff value for TLG<sub>all</sub> but not for TLG<sub>prim</sub> was significantly associated with FFDM (HR&#x02009;=&#x02009;3.1, <italic>p</italic>&#x02009;=&#x02009;0.045). Additional analyses with manually delineated contours of the validation cohort revealed a similar effect (HR&#x02009;=&#x02009;3.47, <italic>p</italic>&#x02009;=&#x02009;0.026). No considerable differences between HPV positive and negative disease were observed.</p></sec><sec><title>Conclusions</title><p id="Par4">TLG<sub>all</sub> is a promising biomarker to select OPC patients with high risk for metachronous distant metastases.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s40644-025-00836-6.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Head and neck squamous cell carcinoma</kwd><kwd>Fluorodeoxyglucose positron emission tomography</kwd><kwd>Oropharynx cancer</kwd><kwd>Total lesion glycolysis</kwd></kwd-group><funding-group><award-group><funding-source><institution>Charit&#x000e9; - Universit&#x000e4;tsmedizin Berlin (3093)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; International Cancer Imaging Society (ICIS) 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">Oropharyngeal squamous cell carcinoma (OPC) is the most prevalent head and neck cancer site in Western countries. Due to its frequent association with prior human papilloma virus (HPV) infection, incidence of this subtype is still increasing in contrast to a decreasing incidence of tobacco induced tumors at other head and neck sites [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. HPV associated OPC is characterized by a favorable prognosis and high radiosensitivity [<xref ref-type="bibr" rid="CR4">4</xref>]. Depending on tumor stage, local control rates range between 80% and 100% [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Due to the high loco-regional control rates, even in locally advanced disease, distant metastases become more clinically relevant. There is some evidence that HPV positive tumors respond more favorably to checkpoint inhibition [<xref ref-type="bibr" rid="CR6">6</xref>]. Given the negative clinical trials on addition of checkpoint inhibition to radiotherapy / chemoradiation (CRT), it is a clinically highly relevant issue to detect patients with high risk for metachronous metastases before initial treatment [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. These patients would be candidates for additional intensified treatment during or after CRT, for example consolidation checkpoint inhibition that has been shown to be highly effective in lung cancer [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par6">Positron emission tomography (PET) staging with the radiotracer 18&#x000a0;F-flurodeoxyglucose (FDG) is standard of care for locally advanced OPC that is treated with definitive CRT [<xref ref-type="bibr" rid="CR10">10</xref>]. Routinely obtained PET parameters can be used as quantitative imaging biomarkers, that can potentially be used for patient stratification. Commonly, these parameters are only evaluated within the primary tumor since delineation of tumor and affected lymph nodes is labour intensive and might be prone to interobserver bias. We have developed a convolutional neuronal network (CNN) to automatically delineate the PET signal of affected head and neck lymph nodes [<xref ref-type="bibr" rid="CR11">11</xref>]. We hypothesized that inclusion of regional lymph nodes improves the ability of quantitative PET parameters to predict distant metastases. Furthermore, the prognostic value was validated in an independent cohort, that was fully automatically delineated by the previously published CNN to ensure fast and reproducible evaluation of this biomarker.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patients and data acquisition</title><p id="Par7">Altogether 431 patients (96 women, 335 men, mean age 61&#x02009;&#x000b1;&#x02009;9y) from three public databases (The Cancer Imaging Archive) and five European centers were included in this study [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. These patients were a subgroup of the patient group already published in [<xref ref-type="bibr" rid="CR18">18</xref>], where only the primary tumor was investigated. Inclusion criteria in this study were: histologically confirmed head and neck squamous cell carcinoma (HNSCC) without evidence of distant metastases, definitive radiotherapy or CRT with curative intent, and availability of an 18&#x000a0;F-FDG- PET prior to therapy. Additional inclusion criteria in the present analysis were: oropharyngeal primary tumor location and availability of a corresponding computed tomography (CT) scan, information on development of distant metastases, and sufficient information to compute standardized uptake values (SUV). In eight cases not all PET positive lymph nodes were fully in the field of view. These eight patients were excluded for further analyses. A summary of patient and tumor characteristics is given in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Note that HPV status was available only for about half of the patients. Data acquisition was performed with eight different PET/CT systems (see [<xref ref-type="bibr" rid="CR18">18</xref>]) and started 88&#x02009;&#x000b1;&#x02009;19&#x000a0;min after injection of 262 to 483 MBq 18&#x000a0;F-FDG. Tomographic images were reconstructed using the standard reconstruction of the corresponding PET/CT system.</p><p id="Par8">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient and tumor characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">Value</th></tr></thead><tbody><tr><td align="left">
<bold>Age (years)</bold>
</td><td align="left"/></tr><tr><td align="left"><p>&#x02003;Mean&#x02009;&#x000b1;SD</p><p>&#x02003;Median</p></td><td align="left"><p>61&#x02009;&#x000b1;&#x02009;9</p><p>61</p></td></tr><tr><td align="left">
<bold>Sex</bold>
</td><td align="left"/></tr><tr><td align="left">&#x02003;Male</td><td align="left">335 (77.7)</td></tr><tr><td align="left">&#x02003;Female</td><td align="left">96 (22.3)</td></tr><tr><td align="left">
<bold>T stage</bold>
</td><td align="left"/></tr><tr><td align="left">&#x02003;Tx</td><td align="left">1 (0.2)</td></tr><tr><td align="left">&#x02003;T1</td><td align="left">50 (11.6)</td></tr><tr><td align="left">&#x02003;T2</td><td align="left">143 (33.2)</td></tr><tr><td align="left">&#x02003;T3</td><td align="left">118 (27.4)</td></tr><tr><td align="left">&#x02003;T4</td><td align="left">117 (27.1)</td></tr><tr><td align="left">
<bold>N stage</bold>
</td><td align="left"/></tr><tr><td align="left">&#x02003;N0</td><td align="left">56 (13)</td></tr><tr><td align="left">&#x02003;N1</td><td align="left">51 (11.8)</td></tr><tr><td align="left">&#x02003;N2</td><td align="left">295 (68.4)</td></tr><tr><td align="left">&#x02003;N3</td><td align="left">25 (5.8)</td></tr><tr><td align="left">
<bold>UICC stage</bold>
</td><td align="left"/></tr><tr><td align="left">&#x02003;I</td><td align="left">4 (0.9)</td></tr><tr><td align="left">&#x02003;II</td><td align="left">23 (5.3)</td></tr><tr><td align="left">&#x02003;III</td><td align="left">63 (14.6)</td></tr><tr><td align="left">&#x02003;IV</td><td align="left">341 (79.1)</td></tr><tr><td align="left">
<bold>HPV status</bold>
</td><td align="left"/></tr><tr><td align="left">&#x02003;n/a</td><td align="left">219 (50.8)</td></tr><tr><td align="left">&#x02003;negative</td><td align="left">89 (20.6)</td></tr><tr><td align="left">&#x02003;positive</td><td align="left">123 (28.5)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec4"><title>Treatment</title><p id="Par9">All patients received primary radiotherapy with curative intent, performed as three-dimensional, intensity modulated or volumetric modulated treatment. Prescribed radiation doses ranged between 66 and 77&#x000a0;Gy (Gy). 366 patients received concomitant systemic therapy, 63 patients received radiotherapy only and 2 patients had no information available on concomitant therapy.</p></sec><sec id="Sec5"><title>Image analysis</title><p id="Par10">For analysis the patient sample was split into an explorative group (<italic>N</italic>&#x02009;=&#x02009;366) and a validation group (<italic>N</italic>&#x02009;=&#x02009;65). The reason for this explicit splitting is based on the training data of the CNN for automatic delineation and explained in detail below. Distribution of clinical parameters were comparable in both groups.</p><p id="Par11">In the explorative group the metabolically active part of the primary tumor and of all PET positive lymph node metastases was delineated in the PET data by an automatic algorithm based on adaptive thresholding considering the local background [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Affected lymphnodes were selected based on FDG uptake or CT parameters. The resulting region of interest (ROI) delineation was inspected visually by an experienced observer (who was blinded to patient outcome) and manually corrected when this was deemed necessary. This was the case in 14 out of 366 primary tumors. Manual correction was more frequent for the lymph nodes: 248 out of 621 lesions. In all cases the reason for manual intervention was a low diffuse tracer accumulation in the respective lesion.</p><p id="Par12">In the validation group the lesions were delineated by application of a previously published CNN [<xref ref-type="bibr" rid="CR11">11</xref>]. This network was trained and tested with the data used in [<xref ref-type="bibr" rid="CR18">18</xref>], which includes the data analyzed in this work. In [<xref ref-type="bibr" rid="CR11">11</xref>] the CNN was tested with external data, i.e. data which had not been used during the training process. The validation group data consists of all data from this independent sample, matching the above mentioned inclusion criteria (availability of CT as well as SUV and oropharyngeal tumor location). CNN based delineation was reviewed but not corrected, resulting in an observer independent delineation. Manually delineated contours were also available for the validation cohort and used for additional validation of robustness. Note that a CNN based delineation of the lesions in the explorative group would not lead to an observer independent delineation. All data in this group were used for CNN training. Application of the CNN to these data would, therefore, introduce a bias towards the delineating observer. Details on the implementation of the CNN to the current data can be found in supplementary methods <xref rid="MOESM1" ref-type="media">1</xref>.</p><p id="Par13">For all delineated ROIs, the parameters maximum and mean SUV (SUV<sub>mean</sub> and SUV<sub>max</sub>), metabolic tumor volume (MTV), and total lesion glycolysis (TLG&#x02009;=&#x02009;MTV&#x000d7;SUV<sub>mean</sub>) were calculated. All three parameters were computed for the primary tumor alone and for primary tumor plus lymph node metastases. In the following we refer to the parameters derived from the primary tumor as SUV<sub>prim</sub>, MTV<sub>prim</sub>, and TLG<sub>prim</sub>, where SUV<sub>prim</sub> is the SUV<sub>max</sub> of the primary tumor. The parameters derived from all lesions were denoted as SUV<sub>all</sub>, MTV<sub>all</sub>, and TLG<sub>all</sub>, where SUV<sub>all</sub> is the overall SUV<sub>max</sub>, MTV<sub>all</sub> is the cumulative volume of primary tumor and lymph nodes, and TLG<sub>all</sub> is the overall SUV<sub>mean</sub> times MTV<sub>all</sub>.</p><p id="Par14">ROI definition and analysis was performed using the ROVER software, version 3.0.47 (ABX, Radeberg, Germany).</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par15">The investigated clinical endpoint was freedom from distant metastases (FFDM) measured from the start of therapy to death and/or event. The association of FFDM with clinically relevant parameters (age, sex, T-stage, N-stage, UICC-stage, chemotherapy yes/no, and HPV status) as well as quantitative PET parameters derived in the explorative group was analyzed using univariate Cox proportional hazard regression in which the PET parameters were included as metric parameters. PET parameters showing a significant effect (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) or a trend for significance (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.1) in this analysis were further analyzed in univariate Cox regression using binarized PET parameters. The cutoff values used for binarization were calculated by performing a univariate Cox regression for each measured value. The values leading to the hazard ratio (HR) with the highest significance were used as cutoff. Hazard ratios were compared using the bootstrap method (10<sup>5</sup> samples) to determine the statistical distribution of (HR1&#x02009;&#x02212;&#x02009;HR2) from which the relevant <italic>P</italic>-value then was derived. In case of a significant difference in HR between parameters derived from the primary tumor and parameters derived from all lesions the corresponding cutoff values were applied to the data in the validation group. The probability of survival was computed and rendered as Kaplan-Meier curves. Independence of parameters was analyzed by multivariate Cox regression, where the clinical parameters, which showed a significant effect in univariate analysis, were included as confounding factors.</p><p id="Par16">Statistical significance was assumed at a <italic>P</italic>-value of less than 0.05. Statistical analysis was performed with the R language and environment for statistical computing version 4.2.2 [<xref ref-type="bibr" rid="CR21">21</xref>].</p></sec></sec><sec id="Sec7"><title>Results</title><p id="Par17">Patient characteristics of the whole cohort of patients are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, patients were predominantly male and had stage IV disease without evidence of distant metastases in PET staging. According to our previous publication on CNN based automatic lymph node segmentation all patients were grouped accordingly. All patients whose data have been used for CNN training of lymph node segmentation, i.e. patients with manually delineated lymphnodes, were used as a training cohort (<italic>n</italic>&#x02009;=&#x02009;366). For independent validation, patients of the CNN validation cohort were used (<italic>n</italic>&#x02009;=&#x02009;65).</p><sec id="Sec8"><title>Explorative analysis</title><p id="Par18">Univariate Cox regression using metric PET parameters revealed MTV<sub>prim</sub>, MTV<sub>all</sub>, and TLG<sub>all</sub> as statistically significant prognostic factors for FFDM. TLG<sub>prim</sub> showed a statistical trend for significance. For SUV<sub>prim</sub> and SUV<sub>all</sub> no significant statistical association with FFDM was observed. Both parameters were therefore excluded from further analyses. Among the investigated clinical parameters only T-stage was a statistical significant prognostic factor. The results for all parameters are shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. All statistically significant metric PET parameters were binarized as described above. In univariate Cox regression the binarized parameters remained statistically significantly associated with the investigated clinical endpoints. Corresponding HRs as well as applied cutoff values can be found in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows Kaplan Meier estimates for TLG<sub>prim</sub> and TLG<sub>all</sub> and the endpoint FFDM in the explorative cohort.</p><p id="Par19">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Univariate Cox regression with respect to FFDM. PET parameters were included as metric parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">HR</th><th align="left">95% CI</th><th align="left"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left">Sex male</td><td align="left">2.18</td><td align="left">0.86&#x02013;5.54</td><td align="left">0.1</td></tr><tr><td align="left">Age&#x02009;<italic>&#x0003e;</italic>&#x02009;61y</td><td align="left">1.49</td><td align="left">0.81&#x02013;2.72</td><td align="left">0.2</td></tr><tr><td align="left">T-stage&#x02009;<italic>&#x0003e;</italic>&#x02009;2</td><td align="left">2.65</td><td align="left">1.38&#x02013;5.09</td><td align="left">
<bold>0.003</bold>
</td></tr><tr><td align="left">N-stage&#x02009;<italic>&#x0003e;</italic>&#x02009;1</td><td align="left">1.8</td><td align="left">0.8&#x02013;4.04</td><td align="left">0.16</td></tr><tr><td align="left">UICC-stage&#x02009;<italic>&#x0003e;</italic>&#x02009;III</td><td align="left">1.7</td><td align="left">0.72&#x02013;4.04</td><td align="left">0.23</td></tr><tr><td align="left">Chemotherapy none</td><td align="left">0.96</td><td align="left">0.43&#x02013;2.16</td><td align="left">0.92</td></tr><tr><td align="left">HPV negative</td><td align="left">1.48</td><td align="left">0.55&#x02013;4</td><td align="left">0.44</td></tr><tr><td align="left">MTV<sub>prim</sub></td><td align="left">1.03</td><td align="left">1&#x02013;1.05</td><td align="left">
<bold>0.022</bold>
</td></tr><tr><td align="left">MTVall</td><td align="left">1.04</td><td align="left">1.02&#x02013;1.06</td><td align="left"><italic>&#x0003c;</italic>&#x02009;<bold>0.001</bold></td></tr><tr><td align="left">TLG<sub>prim</sub></td><td align="left">1.001</td><td align="left">1&#x02013;1.003</td><td align="left">
<bold>0.084</bold>
</td></tr><tr><td align="left">TLGall</td><td align="left">1.002</td><td align="left">1.001&#x02013;1.004</td><td align="left"><italic>&#x0003c;</italic>&#x02009;<bold>0.001</bold></td></tr><tr><td align="left">SUV<sub>prim</sub></td><td align="left">1.02</td><td align="left">0.98&#x02013;1.06</td><td align="left">0.33</td></tr><tr><td align="left">SUVall</td><td align="left">1.03</td><td align="left">0.99&#x02013;1.08</td><td align="left">0.11</td></tr></tbody></table></table-wrap>
</p><p id="Par20">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Univariate Cox regression with respect to FFDM. PET parameters were included as binarized parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Risk</th><th align="left">HR</th><th align="left">95% CI</th><th align="left"><italic>P</italic>&#x02009;value</th></tr></thead><tbody><tr><td align="left">MTV<sub>prim</sub></td><td align="left"><italic>&#x0003e;</italic>&#x02009;16&#x000a0;ml</td><td align="left">2.86</td><td align="left">1.56&#x02013;5.25</td><td align="left"><italic>&#x0003c;</italic>&#x02009;<bold>0.001</bold></td></tr><tr><td align="left">MTV<sub>all</sub></td><td align="left"><italic>&#x0003e;</italic>&#x02009;19&#x000a0;ml</td><td align="left">4.28</td><td align="left">2.23&#x02013;8.2</td><td align="left"><italic>&#x0003c;</italic>&#x02009;<bold>0.001</bold></td></tr><tr><td align="left">TLG<sub>prim</sub></td><td align="left"><italic>&#x0003e;</italic>&#x02009;60&#x000a0;ml</td><td align="left">2.8</td><td align="left">1.48&#x02013;5.31</td><td align="left">
<bold>0.002</bold>
</td></tr><tr><td align="left">TLG<sub>all</sub></td><td align="left"><italic>&#x0003e;</italic>&#x02009;290&#x000a0;ml</td><td align="left">4.32</td><td align="left">2.32&#x02013;8.03</td><td align="left"><italic>&#x0003c;</italic>&#x02009;<bold>0.001</bold></td></tr></tbody></table></table-wrap>
</p><p id="Par21">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Kaplan-Meier curves with respect to FFDM. Results for the explorative group, cutoff values were optimized for this group</p></caption><graphic xlink:href="40644_2025_836_Fig1_HTML" id="d33e1321"/></fig>
</p><p id="Par22">To test if inclusion of lymph nodes led to a significant improvement of the prognostic value compared to evaluation of the primary tumor alone, a pairwise bootstrap analysis was performed as described above. In this analysis TLG<sub>all</sub> showed a statistically significantly increased HR compared to its primary tumor counterpart (<italic>p</italic>&#x02009;=&#x02009;0.02). MTV<sub>all</sub> showed only a statistical trend for significance when compared to MTV<sub>prim</sub> (<italic>p</italic>&#x02009;=&#x02009;0.09).</p><p id="Par23">All four PET parameters (MTV<sub>prim</sub>, MTV<sub>all</sub>, TLG<sub>prim</sub> and TLG<sub>all</sub>) showed a statistically significant association with OS, with all <italic>p</italic>&#x02009;values&#x02009;&#x02264;&#x02009;0.001, see supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>.</p><p id="Par24">Multivariate Cox regression was performed with the statistically significant PET parameters and T-stage (the only significant clinical parameter) for the endpoint FFDM. However, due the strong correlation of MTV<sub>prim</sub>, MTV<sub>all</sub>, TLG<sub>prim</sub>, and TLG<sub>all</sub> (R<sup>2</sup>&#x02009;&#x0003e;&#x02009;0.8) a separate analysis of each of these four parameters together with T-stage was performed. This analysis revealed MTV<sub>all</sub> and TLG<sub>all</sub> as statistically significant (<italic>p</italic>&#x02009;=&#x02009;0.002, <italic>p</italic>&#x02009;=&#x02009;0.031, respectively) factors. No statistically significant effect was found for MTV<sub>prim</sub> and TLG<sub>prim</sub> (<italic>p</italic>&#x02009;=&#x02009;0.58 and <italic>p</italic>&#x02009;=&#x02009;0.87, respectively).</p></sec><sec id="Sec9"><title>Validation</title><p id="Par25">The optimal cutoff values for TLG<sub>prim</sub> and TLG<sub>all</sub>, which were found in the explorative group, were applied the data in the validation group. This revealed a statistically significant effect in univariate Cox regression for TLG<sub>all</sub> (HR&#x02009;=&#x02009;3.1, <italic>p</italic>&#x02009;=&#x02009;0.045). TLG<sub>prim</sub> of the primary tumor alone was not significantly associated with FFDM in this patient group (<italic>p</italic>&#x02009;=&#x02009;0.42). Corresponding Kaplan-Meier curves for the validation cohort are shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. Additional analyses with manually delineated contours of the validation cohort revealed a similar effect (TLG<sub>all</sub> HR&#x02009;=&#x02009;3.47, <italic>p</italic>&#x02009;=&#x02009;0.026), see supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>.</p><p id="Par26">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Kaplan-Meier curves with respect to FFDM. Results for the validation group, cutoff values were taken from the explorative group</p></caption><graphic xlink:href="40644_2025_836_Fig2_HTML" id="d33e1426"/></fig>
</p></sec><sec id="Sec10"><title>HPV subgroup analyses</title><p id="Par27">HPV status was available only for about 50% of the patients. Therefore, a subgroup analysis in HPV positive and negative patients was performed in all available patient data (explorative and validation cohort). Due to the strongly reduced number of patients and the relatively small number of events for the given endpoint we included as many patients as possible in this analysis. Therefore, for evaluation of MTV<sub>prim</sub> and MTV<sub>all</sub> also patients without information on SUV were included, which were excluded in direct comparison of different PET parameters to avoid bias by different numbers of patients (i.e. larger number of patients with MTV versus lower numbers with SUV). By extending the analyzed group of patients we were able to include 251 instead of 161 patients in this analysis. While an analysis in the explorative group alone would have been possible in principle, the validation group would have been too small for this analysis. Note that due to this extension the results below are not validated independently.</p><p id="Par28">Subgroup analyses of patients with known HPV status revealed a similar performance of TLG<sub>all</sub> and MTV<sub>all</sub> in HPV positive and negative patients. In 141 patients with HPV positive OPC, univariate metric cox regression analyses of MTV<sub>prim</sub> and TLG<sub>prim</sub> only showed a statistical trend for association with FFDM (<italic>p</italic>&#x02009;=&#x02009;0.098 and <italic>p</italic>&#x02009;=&#x02009;0.054, respectively), while MTV<sub>all</sub> (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and TLG<sub>all</sub> (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.001) were significantly associated with FFDM. Effects were maintained after binarization and in multivariate testing. Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref> shows Kaplan Meier estimates for HPV positive patients.</p><p id="Par29">In 110 patients with HPV negative OPC, similar associations were seen. While MTV<sub>prim</sub> and TLG<sub>prim</sub> did not show any association with FFDM in metric univariate cox regression analyses, both MTV<sub>all</sub> (<italic>p</italic>&#x02009;=&#x02009;0.016) and TLG<sub>all</sub> (p 0.035) showed a statistically significant association with outcome. The effect was maintained after binarization. No multivariate testing was performed since there were no clinical parameters associated with FFDM in this small sub-group. Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3</xref> shows Kaplan Meier estimates for HPV negative patients.</p></sec></sec><sec id="Sec11"><title>Discussion</title><p id="Par30">Here we were able to show that the semi-quantitative PET parameter TLG<sub>all</sub> was able to stratify patients with a high risk for metachronous distant metastases. This was only the case if primary tumor and all affected lymph nodes were included in the analyses; evaluation of the primary tumor alone did not remain statistically significantly associated with outcome upon independent validation. Importantly, validation was performed in a fully automatically segmented independent group of patients and yielded a significant discrimination of risk groups similar to manually segmented contours of the validation group. We think that this is a very important prerequisite for clinical implementation, since it avoids inter-observer variability and reduces the workload of dedicated physicians.</p><p id="Par31">Prediction of patients at high risk of developing distant metastases during follow-up is an urgent medical need and several publications have developed methods for outcome prediction in HNSCC patients. Wang and colleagues developed a deep learning based model that was able to predict distant metastases in a cohort of 477 head and neck cancer patients. They investigated combined models using CT and PET scans and found out that PET information alone obtains the best model for outcome prediction [<xref ref-type="bibr" rid="CR22">22</xref>]. Ma and colleagues compared several methodological approaches in CT images of OPC patients for outcome prediction [<xref ref-type="bibr" rid="CR23">23</xref>]. Different models showed promising performance to predict distant metastases. Nonetheless, what both models share in common is that they seem to be better in identifying low risk patients who are unlikely to develop distant metastases. Identification of the relatively few high-risk patients seems to be a more difficult, nonetheless clinically very important task. This is a strength of our model that it was able to identify the group of patients with a very high probability (40&#x02013;50%) to develop distant metastases during follow up.</p><p id="Par32">It is surprising that the inclusion of affected lymph nodes only significantly improved FFDM prediction when using TLG, but not when using MTV. This might be due to the sample size of this study, which is nonetheless relatively large compared with other publications on the predictive power of PET for HNSCC outcomes. Therefore, TLG of all lesions might be a better parameter to predict the risk for distant metastases. There is less data on the association of outcome and TLG compared to MTV in HNSCC. A recent review revealed that both MTV and TLG of the primary tumor were associated with OS and disease-free survival (DFS) of HNSCC patients [<xref ref-type="bibr" rid="CR24">24</xref>]. Interestingly, ten studies were included that investigated MTV and DFS, while only five studies reported data on TLG and DFS, and similar disparities existed for the endpoint OS. In a small study on 46 patients with locally advanced laryngeal cancer, TLG of the primary tumor was statistically significantly associated with OS and distant metastases free survival [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par33">Our results are in contrast to a recent retrospective study of 57 patients with HPV associated OPC by Noor and colleagues. They reported a statistical significant association of primary tumor MTV and TLG with DFS and OS. However, nodal and total MTV and TLG did not show an association with outcome of patients [<xref ref-type="bibr" rid="CR26">26</xref>]. This might be an accidental finding since the cohort of Noor was relatively small and the number of events is low in HPV associated tumors. Similar to our findings, Floberg and colleagues reported a significant association of total MTV of all lesions with FFDM but no significant statistical association of primary tumor MTV and FFDM in 153 patients with HPV positive OPC [<xref ref-type="bibr" rid="CR27">27</xref>]. Corresponding TLG data was unfortunately not reported in this study. Data on TLG was reported in another study by Chotchutipan and colleagues that evaluated 142 patients with HPV related OPC. In their analyses, both MTV<sub>all</sub> and TLG<sub>all</sub> were statistically significantly associated with FFDM and remained significantly associated after multivariate testing [<xref ref-type="bibr" rid="CR28">28</xref>]. In that study no direct comparison between both imaging biomarkers was performed, but univariate hazard ratios of TLG were slightly higher than for MTV. Taken together this data is quite similar to our findings in a larger cohort with both HPV positive and negative disease.</p><p id="Par34">Our study has several strengths: To our best knowledge, this is the first study that systematically compared the prognostic value of the primary tumor with the prognostic value of quantitative parameters of all detectable lesions. Additionally, it includes an independent validation cohort that was automatically delineated and could be easily implemented into a clinical workflow for biomarker quantification purposes. Nonetheless, our study also has some limitations, which are mostly inherent to retrospective analyses. This includes missing information on treatment details and follow-up of some patients, missing information on HPV status in several patients and heterogeneity of treatment approaches. Although it is important to note that we tried to minimize this by excluding patients with primary surgical treatment or without sufficient information on distant metastases. The missing HPV status of patients led to very small sub-groups, therefore these results have to be interpreted extremely cautious.</p></sec><sec id="Sec12"><title>Conclusions</title><p id="Par35">In summary, our data identified TLG of primary tumor and affected lymph nodes as a risk factor for the development of metachronous distant metastases in OPC patients treated with primary RT/CRT. We think that this finding merits further prospective validation, as it could potentially be very useful to personalize individual consolidation treatment of high-risk patients.</p></sec><sec id="Sec13" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40644_2025_836_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p>The original online version of this article was revised: Following publication of the original article, we were notified that the equal contribution note was missing: Sebastian Zschaeck and Marina Hajiyianni contributed equally.</p></fn><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Sebastian Zschaeck and Marina Hajiyianni contributed equally.</p></fn><fn><p><bold>Change history</bold></p><p>4/7/2025</p><p>A Correction to this paper has been published: 10.1186/s40644-025-00870-4</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Study conception and design: S.Z. and F.H.; Drafting of manuscript: S.Z. and F.H.; Image processing and analysis: M.H., S.Z., F.H., Study Investigators: S.Z., D.Z., J.v.d.H., P.H., J. K., E.L., G.L., C.B.; Interpretation of data: S.Z., M.H., P.H., P.N., E.K., C.F., P.C., E.L., J.K., A.H., I.S., C.S., C.B., M.B., M.K., G.L., W.C., J.K., D.Z., JvdH., F.H., Final approval of manuscripts: all authors.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL.</p><p>This work was partly supported by the Berliner Krebsgesellschaft (ZSF201720) and by the German Federal Ministry of Education and Research (BMBF contract 03ZIK42/OncoRay). The funders had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par36">This study was approved by the Institutional Ethics Committee of Charit&#x000e9; University Clinic Berlin. Ethics application No. EA1/241/22. Patients treated within prospective studies gave written informed consent to participate. For patients with retrospective evaluation of data, informed consent was waived by the committee due to the retrospective nature of the study.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par37">The authors affirm that human research participants provided informed consent for publication of pseudonymized publication of the data.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par38">Adrien Holzgreve is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)&#x02013; 545058105, and reports compensation for scientific consulting by ABX advanced biochemical compounds outside the submitted work. Dr. Baumann, CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg) is responsible for collaborations with a large number of companies and institutions worldwide. In this capacity, he has signed contracts for research funding and/or collaborations, including commercial transfers, with industry and academia on behalf of his institute(s) and staff. He is a member of several supervisory boards, advisory boards, and boards of trustees. Dr. Baumann confirms that there is no conflict of interest for this paper. Dr. Baumann confirms that, to the best of his knowledge, none of the above funding sources were involved in the preparation of this paper. Dr. Krause received funding for her research projects by IBA (2016), Merck KGaA (2014&#x02013;2018 for preclinical study; 2018&#x02013;2020 for clinical study), Medipan GmbH (2014&#x02013;2018), Attomol GmbH (2019&#x02013;2021), GA Generic Assays GmbH (2019&#x02013;2021), BTU Cottbus-Senftenberg (2019&#x02013;2021), Gesellschaft f&#x000fc;r medizinische und wissenschaftliche genetische Analysen (2019&#x02013;2021), Lipotype GmbH (2019&#x02013;2021), PolyAn GmbH (2019&#x02013;2021). All other authors have nothing to disclose.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>CNN</term><def><p id="Par39">Convolutional neuronal network</p></def></def-item><def-item><term>CRT</term><def><p id="Par40">Radiotherapy / chemoradiation</p></def></def-item><def-item><term>CT</term><def><p id="Par41">Computed tomography</p></def></def-item><def-item><term>FDG</term><def><p id="Par42">18&#x000a0;F-flurodeoxyglucose</p></def></def-item><def-item><term>FFDM</term><def><p id="Par43">Freedom from distant metastases</p></def></def-item><def-item><term>Gy</term><def><p id="Par44">Gray</p></def></def-item><def-item><term>HNSCC</term><def><p id="Par45">Head and neck squamous cell carcinoma</p></def></def-item><def-item><term>HPV</term><def><p id="Par46">Human papilloma virus</p></def></def-item><def-item><term>HR</term><def><p id="Par47">Hazard ratio</p></def></def-item><def-item><term>MTV</term><def><p id="Par48">Metabolic tumor volume</p></def></def-item><def-item><term>OPC</term><def><p id="Par49">Oropharyngeal squamous cell carcinoma</p></def></def-item><def-item><term>OS</term><def><p id="Par50">Overall survival</p></def></def-item><def-item><term>PET</term><def><p id="Par51">Positron emission tomography</p></def></def-item><def-item><term>ROI</term><def><p id="Par52">Region of interest</p></def></def-item><def-item><term>SUV</term><def><p id="Par53">Standardized uptake values</p></def></def-item><def-item><term>TLG</term><def><p id="Par54">Total lesion glycolysis</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Chaturvedi</surname><given-names>AK</given-names></name><name><surname>Anderson</surname><given-names>WF</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Curado</surname><given-names>MP</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers</article-title><source>J Clin Oncol off J Am Soc Clin Oncol</source><year>2013</year><volume>31</volume><fpage>4550</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.50.3870</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol off J Am Soc Clin Oncol. 2013;31:4550&#x02013;9.</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Dyba</surname><given-names>T</given-names></name><name><surname>Randi</surname><given-names>G</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Martos</surname><given-names>C</given-names></name><name><surname>Giusti</surname><given-names>F</given-names></name><name><surname>Nicholson</surname><given-names>N</given-names></name><etal/></person-group><article-title>The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers</article-title><source>Eur J Cancer Oxf Engl 1990</source><year>2021</year><volume>157</volume><fpage>308</fpage><lpage>47</lpage></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer Oxf Engl 1990. 2021;157:308&#x02013;47.</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Mahal</surname><given-names>BA</given-names></name><name><surname>Catalano</surname><given-names>PJ</given-names></name><name><surname>Haddad</surname><given-names>RI</given-names></name><name><surname>Hanna</surname><given-names>GJ</given-names></name><name><surname>Kass</surname><given-names>JI</given-names></name><name><surname>Schoenfeld</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Incidence and demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States</article-title><source>Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol</source><year>2019</year><volume>28</volume><fpage>1660</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-19-0038</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Mahal BA, Catalano PJ, Haddad RI, Hanna GJ, Kass JI, Schoenfeld JD, et al. Incidence and demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2019;28:1660&#x02013;7.</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Ang</surname><given-names>KK</given-names></name><name><surname>Harris</surname><given-names>J</given-names></name><name><surname>Wheeler</surname><given-names>R</given-names></name><name><surname>Weber</surname><given-names>R</given-names></name><name><surname>Rosenthal</surname><given-names>DI</given-names></name><name><surname>Nguyen-T&#x000e2;n</surname><given-names>PF</given-names></name><etal/></person-group><article-title>Human papillomavirus and survival of patients with oropharyngeal cancer</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0912217</pub-id><pub-id pub-id-type="pmid">20530316</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-T&#x000e2;n PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24&#x02013;35.<pub-id pub-id-type="pmid">20530316</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>AC</given-names></name><name><surname>Theurer</surname><given-names>J</given-names></name><name><surname>Prisman</surname><given-names>E</given-names></name><name><surname>Read</surname><given-names>N</given-names></name><name><surname>Berthelet</surname><given-names>E</given-names></name><name><surname>Tran</surname><given-names>E</given-names></name><etal/></person-group><article-title>Randomized Trial of Radiotherapy Versus Transoral robotic surgery for Oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial</article-title><source>J Clin Oncol off J Am Soc Clin Oncol</source><year>2022</year><volume>40</volume><fpage>866</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1200/JCO.21.01961</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Randomized Trial of Radiotherapy Versus Transoral robotic surgery for Oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. J Clin Oncol off J Am Soc Clin Oncol. 2022;40:866&#x02013;75.</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Cohen</surname><given-names>RB</given-names></name><name><surname>D&#x02019;Avella</surname><given-names>CA</given-names></name><name><surname>Singh</surname><given-names>AP</given-names></name><name><surname>Schoenfeld</surname><given-names>JD</given-names></name><name><surname>Hanna</surname><given-names>GJ</given-names></name></person-group><article-title>Overall survival, treatment duration, and rechallenge outcomes with ICI therapy for recurrent or metastatic HNSCC</article-title><source>JAMA Netw Open</source><year>2024</year><volume>7</volume><fpage>e2428526</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.28526</pub-id><pub-id pub-id-type="pmid">39158913</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Sun L, Cohen RB, D&#x02019;Avella CA, Singh AP, Schoenfeld JD, Hanna GJ. Overall survival, treatment duration, and rechallenge outcomes with ICI therapy for recurrent or metastatic HNSCC. JAMA Netw Open. 2024;7:e2428526.<pub-id pub-id-type="pmid">39158913</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Bourhis</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Sire</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Liem</surname><given-names>X</given-names></name><etal/></person-group><article-title>LBA35 avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase III GORTEC-REACH trial</article-title><source>Ann Oncol</source><year>2021</year><volume>32</volume><fpage>S1310</fpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.08.2112</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bourhis J, Tao Y, Sun X, Sire C, Martin L, Liem X, et al. LBA35 avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase III GORTEC-REACH trial. Ann Oncol. 2021;32:S1310.</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>NY</given-names></name><name><surname>Ferris</surname><given-names>RL</given-names></name><name><surname>Psyrri</surname><given-names>A</given-names></name><name><surname>Haddad</surname><given-names>RI</given-names></name><name><surname>Tahara</surname><given-names>M</given-names></name><name><surname>Bourhis</surname><given-names>J</given-names></name><etal/></person-group><article-title>Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial</article-title><source>Lancet Oncol</source><year>2021</year><volume>22</volume><fpage>450</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(20)30737-3</pub-id><pub-id pub-id-type="pmid">33794205</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22:450&#x02013;62.<pub-id pub-id-type="pmid">33794205</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al. Overall survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018.</mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Mehanna</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>W-L</given-names></name><name><surname>McConkey</surname><given-names>CC</given-names></name><name><surname>Rahman</surname><given-names>JK</given-names></name><name><surname>Robinson</surname><given-names>M</given-names></name><name><surname>Hartley</surname><given-names>AGJ</given-names></name><etal/></person-group><article-title>PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer</article-title><source>N Engl J Med</source><year>2016</year><volume>374</volume><fpage>1444</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1514493</pub-id><pub-id pub-id-type="pmid">27007578</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M, Hartley AGJ, et al. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. N Engl J Med. 2016;374:1444&#x02013;54.<pub-id pub-id-type="pmid">27007578</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Nikulin</surname><given-names>P</given-names></name><name><surname>Zschaeck</surname><given-names>S</given-names></name><name><surname>Maus</surname><given-names>J</given-names></name><name><surname>Cegla</surname><given-names>P</given-names></name><name><surname>Lombardo</surname><given-names>E</given-names></name><name><surname>Furth</surname><given-names>C</given-names></name><etal/></person-group><article-title>A convolutional neural network with self-attention for fully automated metabolic tumor volume delineation of head and neck cancer in [Formula: see text]F]FDG PET/CT</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2023</year><volume>50</volume><fpage>2751</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/s00259-023-06197-1</pub-id><pub-id pub-id-type="pmid">37079128</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Nikulin P, Zschaeck S, Maus J, Cegla P, Lombardo E, Furth C, et al. A convolutional neural network with self-attention for fully automated metabolic tumor volume delineation of head and neck cancer in [Formula: see text]F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2023;50:2751&#x02013;66.<pub-id pub-id-type="pmid">37079128</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Beichel RR, Ulrich EJ, Bauer C, Wahle A, Brown B, Chang T et al. Data From QIN-HEADNECK. 2015 [cited 2020 Jun 10]; Available from: <ext-link ext-link-type="uri" xlink:href="https://wiki.cancerimagingarchive.net/x/qQ9p">https://wiki.cancerimagingarchive.net/x/qQ9p</ext-link></mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>K</given-names></name><name><surname>Vendt</surname><given-names>B</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Freymann</surname><given-names>J</given-names></name><name><surname>Kirby</surname><given-names>J</given-names></name><name><surname>Koppel</surname><given-names>P</given-names></name><etal/></person-group><article-title>The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository</article-title><source>J Digit Imaging</source><year>2013</year><volume>26</volume><fpage>1045</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1007/s10278-013-9622-7</pub-id><pub-id pub-id-type="pmid">23884657</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, et al. The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging. 2013;26:1045&#x02013;57.<pub-id pub-id-type="pmid">23884657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Grossberg</surname><given-names>AJ</given-names></name><name><surname>Mohamed</surname><given-names>ASR</given-names></name><name><surname>Elhalawani</surname><given-names>H</given-names></name><name><surname>Bennett</surname><given-names>WC</given-names></name><name><surname>Smith</surname><given-names>KE</given-names></name><name><surname>Nolan</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy</article-title><source>Sci Data</source><year>2018</year><volume>5</volume><fpage>180173</fpage><pub-id pub-id-type="doi">10.1038/sdata.2018.173</pub-id><pub-id pub-id-type="pmid">30179230</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Grossberg AJ, Mohamed ASR, Elhalawani H, Bennett WC, Smith KE, Nolan TS, et al. Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Sci Data. 2018;5:180173.<pub-id pub-id-type="pmid">30179230</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Valli&#x000e8;res M, Kay-Rivest E, Perrin L, Liem X, Furstoss C, Khaouam N et al. Data from Head-Neck-PET-CT [Internet]. The Cancer Imaging Archive; 2017 [cited 2020 Jun 10]. Available from: <ext-link ext-link-type="uri" xlink:href="https://wiki.cancerimagingarchive.net/x/24pyAQ">https://wiki.cancerimagingarchive.net/x/24pyAQ</ext-link></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Wee L, Dekker A. Data from Head-Neck-Radiomics-HN1 [Internet]. The Cancer Imaging Archive; 2019 [cited 2020 Oct 13]. Available from: <ext-link ext-link-type="uri" xlink:href="https://wiki.cancerimagingarchive.net/x/iBglAw">https://wiki.cancerimagingarchive.net/x/iBglAw</ext-link></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Zuley ML, Jarosz R, Kirk S, Lee Y, Colen R, Garcia K et al. Radiology Data from The Cancer Genome Atlas Head-Neck Squamous Cell Carcinoma [TCGA-HNSC] collection [Internet]. The Cancer Imaging Archive; 2016 [cited 2020 Oct 13]. Available from: <ext-link ext-link-type="uri" xlink:href="https://wiki.cancerimagingarchive.net/x/VYG0">https://wiki.cancerimagingarchive.net/x/VYG0</ext-link></mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Zschaeck</surname><given-names>S</given-names></name><name><surname>Weing&#x000e4;rtner</surname><given-names>J</given-names></name><name><surname>Lombardo</surname><given-names>E</given-names></name><name><surname>Marschner</surname><given-names>S</given-names></name><name><surname>Hajiyianni</surname><given-names>M</given-names></name><name><surname>Beck</surname><given-names>M</given-names></name><etal/></person-group><article-title>18F-Fluorodeoxyglucose Positron Emission Tomography of Head and Neck Cancer: location and HPV specific parameters for potential treatment individualization</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>870319</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.870319</pub-id><pub-id pub-id-type="pmid">35756665</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Zschaeck S, Weing&#x000e4;rtner J, Lombardo E, Marschner S, Hajiyianni M, Beck M, et al. 18F-Fluorodeoxyglucose Positron Emission Tomography of Head and Neck Cancer: location and HPV specific parameters for potential treatment individualization. Front Oncol. 2022;12:870319.<pub-id pub-id-type="pmid">35756665</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Hofheinz</surname><given-names>F</given-names></name><name><surname>Langner</surname><given-names>J</given-names></name><name><surname>Petr</surname><given-names>J</given-names></name><name><surname>Beuthien-Baumann</surname><given-names>B</given-names></name><name><surname>Steinbach</surname><given-names>J</given-names></name><name><surname>Kotzerke</surname><given-names>J</given-names></name><etal/></person-group><article-title>An automatic method for accurate volume delineation of heterogeneous tumors in PET</article-title><source>Med Phys</source><year>2013</year><volume>40</volume><fpage>082503</fpage><pub-id pub-id-type="doi">10.1118/1.4812892</pub-id><pub-id pub-id-type="pmid">23927348</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Hofheinz F, Langner J, Petr J, Beuthien-Baumann B, Steinbach J, Kotzerke J, et al. An automatic method for accurate volume delineation of heterogeneous tumors in PET. Med Phys. 2013;40:082503.<pub-id pub-id-type="pmid">23927348</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Hofheinz</surname><given-names>F</given-names></name><name><surname>P&#x000f6;tzsch</surname><given-names>C</given-names></name><name><surname>Oehme</surname><given-names>L</given-names></name><name><surname>Beuthien-Baumann</surname><given-names>B</given-names></name><name><surname>Steinbach</surname><given-names>J</given-names></name><name><surname>Kotzerke</surname><given-names>J</given-names></name><etal/></person-group><article-title>Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets</article-title><source>Nukl Nucl Med</source><year>2012</year><volume>51</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1055/s-00034924</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Hofheinz F, P&#x000f6;tzsch C, Oehme L, Beuthien-Baumann B, Steinbach J, Kotzerke J, et al. Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets. Nukl Nucl Med. 2012;51:9&#x02013;16.</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">R Core Team. R: a Language and Environment for Statistical Computing. R Found Stat Comput.</mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lombardo</surname><given-names>E</given-names></name><name><surname>Avanzo</surname><given-names>M</given-names></name><name><surname>Zschaek</surname><given-names>S</given-names></name><name><surname>Weing&#x000e4;rtner</surname><given-names>J</given-names></name><name><surname>Holzgreve</surname><given-names>A</given-names></name><etal/></person-group><article-title>Deep learning based time-to-event analysis with PET, CT and joint PET/CT for head and neck cancer prognosis</article-title><source>Comput Methods Programs Biomed</source><year>2022</year><volume>222</volume><fpage>106948</fpage><pub-id pub-id-type="doi">10.1016/j.cmpb.2022.106948</pub-id><pub-id pub-id-type="pmid">35752119</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Wang Y, Lombardo E, Avanzo M, Zschaek S, Weing&#x000e4;rtner J, Holzgreve A, et al. Deep learning based time-to-event analysis with PET, CT and joint PET/CT for head and neck cancer prognosis. Comput Methods Programs Biomed. 2022;222:106948.<pub-id pub-id-type="pmid">35752119</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>van Dijk</surname><given-names>LV</given-names></name><name><surname>van Ooijen</surname><given-names>PMA</given-names></name><name><surname>Langendijk</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Comparison of computed tomography image features extracted by radiomics, self-supervised learning and end-to-end deep learning for outcome prediction of oropharyngeal cancer</article-title><source>Phys Imaging Radiat Oncol</source><year>2023</year><volume>28</volume><fpage>100502</fpage><pub-id pub-id-type="doi">10.1016/j.phro.2023.100502</pub-id><pub-id pub-id-type="pmid">38026084</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Ma B, Guo J, Chu H, van Dijk LV, van Ooijen PMA, Langendijk JA, et al. Comparison of computed tomography image features extracted by radiomics, self-supervised learning and end-to-end deep learning for outcome prediction of oropharyngeal cancer. Phys Imaging Radiat Oncol. 2023;28:100502.<pub-id pub-id-type="pmid">38026084</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name></person-group><article-title>Prognostic value of MTV and TLG of 18 F-FDG PET in patients with head and neck squamous cell carcinoma: a meta-analysis</article-title><source>Med (Baltim)</source><year>2022</year><volume>101</volume><fpage>e30798</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000030798</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Jin A, Lin X, Yin X, Cui Y, Ma L. Prognostic value of MTV and TLG of 18 F-FDG PET in patients with head and neck squamous cell carcinoma: a meta-analysis. Med (Baltim). 2022;101:e30798.</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Tamaki</surname><given-names>T</given-names></name><name><surname>Terada</surname><given-names>H</given-names></name><name><surname>Nishio</surname><given-names>M</given-names></name><name><surname>Nishikawa</surname><given-names>D</given-names></name><name><surname>Beppu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Total lesion glycolysis as a predictor of clinical T3-4a laryngeal cancer with laryngectomy or nonlaryngectomy</article-title><source>Med (Baltim)</source><year>2021</year><volume>100</volume><fpage>e27427</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000027427</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Suzuki H, Tamaki T, Terada H, Nishio M, Nishikawa D, Beppu S, et al. Total lesion glycolysis as a predictor of clinical T3-4a laryngeal cancer with laryngectomy or nonlaryngectomy. Med (Baltim). 2021;100:e27427.</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Noor</surname><given-names>A</given-names></name><name><surname>Mair</surname><given-names>M</given-names></name><name><surname>Cook</surname><given-names>L</given-names></name><name><surname>Bolt</surname><given-names>H</given-names></name><name><surname>Cheriyan</surname><given-names>S</given-names></name><name><surname>Woods</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Prognostic value of 18 F-Fluoro-deoxyglucose-Positron Emission Tomography Volumetric parameters in Human Papillomavirus-related Oropharyngeal squamous cell carcinoma</article-title><source>Laryngoscope</source><year>2023</year><volume>133</volume><fpage>1667</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1002/lary.30362</pub-id><pub-id pub-id-type="pmid">36053907</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Noor A, Mair M, Cook L, Bolt H, Cheriyan S, Woods CM, et al. Prognostic value of 18 F-Fluoro-deoxyglucose-Positron Emission Tomography Volumetric parameters in Human Papillomavirus-related Oropharyngeal squamous cell carcinoma. Laryngoscope. 2023;133:1667&#x02013;72.<pub-id pub-id-type="pmid">36053907</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Floberg</surname><given-names>JM</given-names></name><name><surname>DeWees</surname><given-names>TA</given-names></name><name><surname>Chin</surname><given-names>R-I</given-names></name><name><surname>Garsa</surname><given-names>AA</given-names></name><name><surname>Dehdashti</surname><given-names>F</given-names></name><name><surname>Nussenbaum</surname><given-names>B</given-names></name><etal/></person-group><article-title>Pretreatment metabolic tumor volume as a prognostic factor in HPV-associated oropharyngeal cancer in the context of AJCC 8th edition staging</article-title><source>Head Neck</source><year>2018</year><volume>40</volume><fpage>2280</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/hed.25337</pub-id><pub-id pub-id-type="pmid">30051553</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Floberg JM, DeWees TA, Chin R-I, Garsa AA, Dehdashti F, Nussenbaum B, et al. Pretreatment metabolic tumor volume as a prognostic factor in HPV-associated oropharyngeal cancer in the context of AJCC 8th edition staging. Head Neck. 2018;40:2280&#x02013;7.<pub-id pub-id-type="pmid">30051553</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Chotchutipan</surname><given-names>T</given-names></name><name><surname>Rosen</surname><given-names>BS</given-names></name><name><surname>Hawkins</surname><given-names>PG</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Saripalli</surname><given-names>AL</given-names></name><name><surname>Thakkar</surname><given-names>D</given-names></name><etal/></person-group><article-title>Volumetric 18 F-FDG-PET parameters as predictors of locoregional failure in low-risk HPV-related oropharyngeal cancer after definitive chemoradiation therapy</article-title><source>Head Neck</source><year>2019</year><volume>41</volume><fpage>366</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1002/hed.25505</pub-id><pub-id pub-id-type="pmid">30548704</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Chotchutipan T, Rosen BS, Hawkins PG, Lee JY, Saripalli AL, Thakkar D, et al. Volumetric 18 F-FDG-PET parameters as predictors of locoregional failure in low-risk HPV-related oropharyngeal cancer after definitive chemoradiation therapy. Head Neck. 2019;41:366&#x02013;73.<pub-id pub-id-type="pmid">30548704</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>